Gatifloxacin precipitation of psychosis in alzheimer disease [3]

American Journal of Geriatric Psychiatry

Volumn 11, Issue 4, 2003, Pages 470-471

  Reeves, Roy R ^a   Montgomery, G V ^a  

^a UNIVERSITY OF MISSISSIPPI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; GATIFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RISPERIDONE;

AGED; AGITATION; ALZHEIMER DISEASE; BRAIN ATROPHY; BRONCHITIS; CASE REPORT; CLINICAL FEATURE; DOSE RESPONSE; DROWSINESS; DRUG ACTIVITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; GRAND MAL SEIZURE; HALLUCINATION; HEADACHE; HUMAN; INSOMNIA; LETTER; MALE; MYOCLONUS; PSYCHOSIS; RESTLESSNESS; SEIZURE; SIDE EFFECT; SLEEP DISORDER; TREMOR; UNPLEASANT DREAM; VERTIGO; VISUAL DISORDER;

EID: 0038048136     PISSN: 10647481     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019442-200307000-00015     Document Type: Letter

References (5)

1. Fish DN, North DS: Gatifloxacin, an advanced 8-methoxy-fluoroquinolone. Pharmacotherapy 2001; 21:35-59
2. Fish DN: Fluoroquinolone: adverse effects and drug interactions. Pharmacotherapy 2001; 21(10 pt2:253S-272S)
3. Jick SS, Jick H, Dean AD: A follow-up safety study of ciprofloxacin users. Pharmacotherapy 1993; 13:461-464
4. Jungst G, Mohr R: Side effects ofofloxacin in clinical trials and in postmarketing surveillance. Drugs 1987; 34(suppl):144-149
5. Marinella MA: Myoclonus and generalized seizures associated with gatifloxacin treatment. Arch Intern Med 2001; 2261-2262